Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics

Tenaya Therapeutics, Inc. (TNYA): $5.26

0.10 (+1.94%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add TNYA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#171 of 363

in industry

TNYA Price/Volume Stats

Current price $5.26 52-week high $8.09
Prev. close $5.16 52-week low $1.66
Day low $5.06 Volume 70,577
Day high $5.30 Avg. volume 624,234
50-day MA $5.16 Dividend yield N/A
200-day MA $3.86 Market Cap 412.99M

TNYA Stock Price Chart Interactive Chart >


Tenaya Therapeutics, Inc. (TNYA) Company Bio


Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.


TNYA Latest News Stream


Event/Time News Detail
Loading, please wait...

TNYA Latest Social Stream


Loading social stream, please wait...

View Full TNYA Social Stream

Latest TNYA News From Around the Web

Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 35th Annual Piper Sandler Healthcare Conference taking place in New York, NY. Details of participation are as follows: Fireside ChatDate: Novem

Yahoo | November 21, 2023

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Commenced Patient Dosing in MyPeak-1TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 TN-401 for PKP2-Associated ARVC Received FDA Clearance to Begin First-in-Human Clinical Testing and Fast Track Designation SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechn

Yahoo | November 8, 2023

Institutional investors have a lot riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) with 38% ownership

Key Insights Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their...

Yahoo | November 6, 2023

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated Robust Reduction of Ventricular Arrhythmias and Extended Survival in Knockout Models of Disease After a Single Dose SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and

Yahoo | October 26, 2023

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | October 10, 2023

Read More 'TNYA' Stories Here

TNYA Price Returns

1-mo -9.93%
3-mo 62.35%
6-mo 106.27%
1-year 94.81%
3-year N/A
5-year N/A
YTD 62.35%
2023 61.19%
2022 -89.39%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!